相关实验视频
Updated: Dec 21, 2025

13:00
Engineering Antiviral Agents via Surface Plasmon Resonance
Published on: June 14, 2022
2.6K
一对非竞争性的人类中和抗体阻断COVID-19病毒与其受体ACE2结合
Yan Wu1,2, Feiran Wang3,4, Chenguang Shen3,5
1Department of Pathogen Microbiology, School of Basic Medical Sciences, Capital Medical University, Beijing, China. wuy@biols.ac.cn gaofeng@tib.cas.cn gaof@im.ac.cn liulei3322@aliyun.com.
概括
分离了四种人类单克隆抗体,其中B38和H4阻断了SARS-CoV-2尖端蛋白与ACE2的结合. 这些中和抗体显示出COVID-19治疗方法和疫苗设计的前景.
科学领域:
- 免疫学
- 病毒学
- 结构生物学
背景情况:
- 中和抗体是2019年冠状病毒病 (COVID-19) 的潜在抗病毒策略.
- 鉴定有力的中和抗体对于开发有效的COVID-19治疗方法至关重要.
研究的目的:
- 针对SARS-CoV-2具有中和活性的人类单克隆抗体的分离和特征.
- 调查有希望的抗体候选者的中和机制.
- 在临床前模型中评估这些抗体的治疗潜力.
主要方法:
- 从康复的COVID-19患者中分离单克隆抗体.
- 结合测试用于评估与SARS-CoV-2尖端蛋白受体结合域 (RBD) 的抗体相互作用.
- 竞争测试以确定抗体表位结合.
- 在COVID-19小鼠模型中进行治疗疗效研究.
- 用X射线结晶学来确定抗体与RBD相互作用的结构基础.
主要成果:
- 分离了具有中和能力的四种人类单克隆抗体.
- 发现B38和H4抗体阻断病毒RBD与人类ACE2受体之间的相互作用.
- 竞争分析显示了B38和H4在RBD上的不同表位.
- 这些抗体的治疗治疗降低了感染小鼠的肺部病毒标位.
- 结构分析显示B38表位与RBD-ACE2结合界面有显著的重叠.
结论:
- 人类单克隆抗体,特别是B38和H4,通过阻断RBD-ACE2相互作用,表现出强大的中和活性.
- 针对B38和H4的特异性表位表明组合疗法有潜力克服免疫逃逸.
- 这些发现支持基于抗体的COVID-19治疗方法的开发,并为合理的疫苗设计提供了见解.
更多相关视频
相关概念视频
Antibody Actions
2.2K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
2.2K
Cross-reactivity
32.7K
Overview
32.7K
Drug-Receptor Interaction: Antagonist
4.5K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
4.5K
Combined Effects of Drugs: Antagonism
11.3K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
11.3K
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
2.6K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
2.6K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
795
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
795

